Baird Financial Group Inc. Sells 37,027 Shares of Edwards Lifesciences Corporation (EW)

Baird Financial Group Inc. lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 6.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 509,706 shares of the medical research company’s stock after selling 37,027 shares during the period. Baird Financial Group Inc. owned about 0.24% of Edwards Lifesciences Corporation worth $47,759,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. State Street Corp raised its position in shares of Edwards Lifesciences Corporation by 4.6% in the fourth quarter. State Street Corp now owns 9,231,150 shares of the medical research company’s stock valued at $864,955,000 after buying an additional 409,899 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Edwards Lifesciences Corporation by 1.5% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 5,542,619 shares of the medical research company’s stock valued at $668,218,000 after buying an additional 81,691 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Edwards Lifesciences Corporation by 3.4% in the third quarter. BlackRock Fund Advisors now owns 4,337,584 shares of the medical research company’s stock valued at $522,939,000 after buying an additional 143,348 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of Edwards Lifesciences Corporation by 1.6% in the third quarter. Ameriprise Financial Inc. now owns 4,320,603 shares of the medical research company’s stock valued at $520,896,000 after buying an additional 66,627 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of Edwards Lifesciences Corporation by 0.7% in the third quarter. Northern Trust Corp now owns 2,620,280 shares of the medical research company’s stock valued at $315,902,000 after buying an additional 19,503 shares in the last quarter. 83.99% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Edwards Lifesciences Corporation (NYSE:EW) traded down 0.0848% during midday trading on Friday, hitting $89.8537. The company’s stock had a trading volume of 216,116 shares. The company’s 50-day moving average is $94.40 and its 200 day moving average is $102.51. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75. The company has a market cap of $19.20 billion, a price-to-earnings ratio of 34.4267 and a beta of 0.53.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Wednesday, February 1st. The medical research company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. The firm earned $767.70 million during the quarter, compared to analysts’ expectations of $760.85 million. Edwards Lifesciences Corporation had a return on equity of 25.00% and a net margin of 19.22%. The firm’s quarterly revenue was up 14.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.64 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post $3.40 EPS for the current year.

“Baird Financial Group Inc. Sells 37,027 Shares of Edwards Lifesciences Corporation (EW)” was published by Mideast Time and is the sole property of of Mideast Time. If you are viewing this story on another publication, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.mideasttime.com/baird-financial-group-inc-sells-37027-shares-of-edwards-lifesciences-corporation-ew/1541346.html.

Several equities analysts have recently weighed in on EW shares. Jefferies Group LLC restated a “buy” rating and set a $115.00 price target (down from $125.00) on shares of Edwards Lifesciences Corporation in a report on Wednesday, October 26th. Northland Securities restated a “positive” rating and set a $105.00 price target on shares of Edwards Lifesciences Corporation in a report on Thursday, February 2nd. Canaccord Genuity set a $140.00 price target on Edwards Lifesciences Corporation and gave the company a “buy” rating in a report on Monday, November 28th. Leerink Swann downgraded Edwards Lifesciences Corporation from an “outperform” rating to a “market perform” rating in a report on Thursday, February 2nd. Finally, Credit Suisse Group set a $120.00 price target on Edwards Lifesciences Corporation and gave the company a “buy” rating in a report on Wednesday, February 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and nineteen have issued a buy rating to the stock. Edwards Lifesciences Corporation has a consensus rating of “Buy” and an average price target of $116.54.

In related news, Director Kieran Gallahue acquired 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 29th. The stock was purchased at an average cost of $84.63 per share, for a total transaction of $253,890.00. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 49,100 shares of the company’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $84.67, for a total value of $4,157,297.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have purchased 68,870 shares of company stock valued at $1,604,434 and have sold 187,928 shares valued at $17,001,801. Corporate insiders own 2.37% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting.

5 Day Chart for NYSE:EW

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.